Skip to main content
Chison Medical Technologies Co.,Ltd. logo

Chison Medical Technologies Co.,Ltd. — Investor Relations & Filings

Ticker · 688358 ISIN · CNE1000076R4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 686 across all filing types
Latest filing 2023-01-06 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688358

About Chison Medical Technologies Co.,Ltd.

https://www.chison.com/

Chison Medical Technologies Co.,Ltd. specializes in the research, development, and manufacturing of diagnostic ultrasound systems. The company offers a comprehensive portfolio of medical imaging solutions, including trolley-based color Doppler systems, portable ultrasound units, and specialized handheld devices. Its products integrate advanced imaging technologies such as 4D imaging, artificial intelligence-assisted diagnostics, and high-resolution transducers to support clinical applications in cardiology, obstetrics, gynecology, and point-of-care settings. Chison focuses on delivering high-performance diagnostic tools to healthcare providers, supported by a global network of research centers and distribution channels. The company emphasizes continuous innovation in digital signal processing and transducer technology to enhance diagnostic accuracy and clinical workflow efficiency.

Recent filings

Filing Released Lang Actions
国金证券股份有限公司关于无锡祥生医疗科技股份有限公司2022年度持续督导现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2022年度持续督导现场检查报告" (2022 Annual Continuous Supervision On-site Inspection Report) issued by Guojin Securities Co., Ltd. as the sponsor institution for Wuxi Xiangsheng Medical Technology Co., Ltd. It details the on-site inspection covering governance, internal control, information disclosure, independence, related party transactions, use of raised funds, and operational status during the supervision period. The document references regulatory rules and guidelines from the Shanghai Stock Exchange and China Securities Regulatory Commission. It is a standalone audit or supervisory report focusing on compliance and internal controls rather than a full annual report or financial statement. The length is about 2483 characters, which is consistent with a detailed audit or supervisory report rather than a brief announcement or a full annual report. Therefore, the document fits best under the category of Audit Report / Information (AR). FY 2022
2023-01-06 Chinese
国金证券股份有限公司关于无锡祥生医疗科技股份有限公司首次公开发行限售股上市流通的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from Guojin Securities regarding the listing and circulation of restricted shares from the initial public offering of Wuxi Xiangsheng Medical Technology Co., Ltd. It includes legal references, shareholding details, lock-up commitments, and confirms compliance with relevant laws and regulations. The document is not a financial report, earnings release, or management discussion, but rather a formal verification and opinion related to share circulation post-IPO. This fits the category of a Regulatory Filing (RNS) as it is a compliance and verification announcement that does not fit other specific categories like capital updates or director dealings.
2022-12-01 Chinese
祥生医疗首次公开发行限售股上市流通公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Wuxi Xiangsheng Medical Technology Co., Ltd. regarding the listing and circulation of restricted shares that were previously locked following the company's initial public offering (IPO). It details the number of shares becoming freely tradable, the lock-up period expiration, shareholder commitments, and regulatory compliance confirmations. The document references regulatory approvals and compliance with stock exchange rules but does not contain financial statements or detailed financial performance data. It is primarily a disclosure about share circulation and shareholder commitments related to restricted shares becoming tradable. This fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement about share circulation and compliance rather than a financial report or a voting result announcement.
2022-12-01 Chinese
上海市通力律师事务所关于无锡祥生医疗科技股份有限公司2022年第三次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the 2022 third extraordinary general meeting (临时股东大会) of Wuxi Xiangsheng Medical Technology Co., Ltd. It details the legality of the meeting's convening, attendance, voting procedures, and results. The document includes voting results on several proposals and confirms the legality and validity of the meeting and its resolutions. It is not a full annual or interim report, nor an earnings release or management discussion. It is not a proxy solicitation or a voting results announcement per se, but a legal opinion supporting the meeting and its outcomes. Given the content and purpose, this document best fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it relates to shareholder meeting voting results and their legal validation. The document length is under 5,000 characters, but it contains substantive voting results and legal opinion, not just an announcement of a report publication. Therefore, the classification is DVA with high confidence.
2022-11-15 Chinese
祥生医疗2022年第三次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement of the resolutions passed at the third extraordinary general meeting of shareholders of Wuxi Xiangsheng Medical Technology Co., Ltd. It includes details about the meeting date, attendance, voting results on various proposals, and legal witness statements. The content focuses on the voting outcomes and procedural compliance rather than presenting a full report or financial statements. The document length is relatively short (2040 characters) and it serves as an official disclosure of voting results from a shareholders' meeting. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2022-11-15 Chinese
祥生医疗关于召开2022年第三季度业绩说明会的公告
Call Transcript Classification · 80% confidence The document is an announcement about the scheduling and details of a 2022 third quarter earnings explanation meeting (业绩说明会) for Wuxi Xiangsheng Medical Technology Co., Ltd. It provides the date, time, location, participation method, and contact information for the meeting. It references the previously disclosed 2022 third quarter report but does not contain actual financial data or the report itself. The document is essentially an invitation and information notice for an earnings call or earnings explanation session, which aligns with the category of a Call Transcript (CT) or an Earnings Release (ER). However, since it is announcing the meeting rather than providing the transcript or the initial earnings highlights, it is best classified as a Call Transcript (CT) type document because it is about the earnings explanation meeting where Q&A will occur. The document length is short and it does not contain financial statements, so it is not an Interim/Quarterly Report (IR). Therefore, the best fit is Call Transcript (CT) with moderate confidence due to the nature of the announcement about the earnings explanation meeting.
2022-11-04 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.